Expert Discusses Evolving Role of Genetic Testing in Prostate Cancer
James L. Mohler, MD, discusses the evolving role of genetic testing in patients with prostate cancer following the updates to the National Cancer Care Network Guidelines, which now include guidance for better practice in terms of conducting genetic testing in this patient population.
James L. Mohler, MD, associate director and senior vice president for translational research, and professor of oncology, Roswell Park Comprehensive Cancer Center, discusses the evolving role of genetic testing in patients with prostate cancer following the updates to the National Cancer Care Network (NCCN) Guidelines, which now include guidance for better practice in terms of conducting genetic testing in this patient population.
The importance of genetic testing has been recognized, says Mohler, but there is a deficient in the number of highly trained and qualified genetic counselors. Although physicians are functioning well despite these odds, certificate programs are available that provide more individuals with short courses to improve on their knowledge of genetic testing so that physicians can do a better job at pre-genetic testing counseling.
As a urologist, Mohler says that he lacks in this area of expertise as well, which is why more genetic counselors need to be trained.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
